All News

Sparks RNL26

Advances in RA-ILD

Richard Conway, MBBChBAO, PhD

Dr. Jeffrey Sparks gave a state of the art update on Advances in RA-ILD, many of which he and his group have played a big part in, on Saturday at RNL26. 

Read Article
Gout pills injection

SGLT2 Inhibitors in Gout - Better Outcomes, Fewer Meds

EurekAlert!

Natalie McCormick, PhD, of the Rheumatology and Allergy Clinical Epidemiology Research (RACER) Center within the Division of Rheumatology in the Mass General Brigham Department of Medicine

Read Article
Aorta

Aortitis in Giant Cell Arteritis Treated with Tocilizumab

Jack Cush, MD

The The Tocilizumab in Giant Cell Arteritis Spanish Collaborative Group studied giant cell arteritis with aortitis, comparing the efficacy of intravenous vs. subcutaneously (SC) tocilizumab (TCZ) - demonstrating the superiority of SC TCZ.

Read Article
death

Trends in Rheumatoid Arthritis Mortality

Jack Cush, MD

A recent study examines trends in rheumatoid arthritis (RA)-related mortality among U.S. postmenopausal women (aged 55 and older). They found RA mortality rates have declined, yet disparities in who is most affected persist, especially for white women, and those over 85 yrs of age.

Read Article
RheumNow Podcast square

Emergencies, Independence & Hemorrhage (1.23.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news and reports from the past two weeks on RheumNow.Com

Read Article
2025

The 2025 Rheumatology Year in Review

Jack Cush, MD

The year 2025 presented numerous advances in rheumatology and related inflammatory and autoimmune disorders ranging from several new groundbreaking FDA approvals/indications, drug developments, game-changing guidelines and practices that will impact patient care for rheumatic diseases.

Read Article
alveolar hemorrhage acute

Diffuse Alveolar Hemorrhage in Rheumatic Disease

Jack Cush, MD

A retrospective, cross-sectional, single-center study of adult rheumatic disease patients with diffuse alveolar hemorrhage (DAH), demonstrates a high proportion have coexistent pulmonary infection and significant mortality risk. 

Read Article
RT @richardPAconway Dr Sparks. RA-ILD is common. Pooled prevalence of 11% from recent meta-analysis. Less common than SSc or IIM, but more frequent than we think! #RNL26 https://t.co/TCsDfeQjZC
Dr. John Cush RheumNow ( View Tweet)
RT @ericdeinmd Mortality risk in RA #RNL26 Myasoedova Most common mortality: 1.5-1.6x increase risk CVD 2-3x increase risk ILD +ACPA increases risk in both https://t.co/Luwyy6UFg6
Dr. John Cush RheumNow ( View Tweet)
NEJM: Aortitis Due to Large-Vessel Vasculitis 63yoM w/ Hx HTN c/o 3 mos of CP, palpitations, abdominal pain. ESR-104, CRP 85 mg/L. CT showed thickening of the thoracic & abdominal aorta. After 6wks Rx w/ AZA, HCQ, Pred, ESR/CRP still high and pt stared on SC TCZ w/ improvement. https://t.co/1TBreptAFr
Dr. John Cush RheumNow ( View Tweet)
NEJM: Aortitis Due to Large-Vessel Vasculitis 63yoM w/ Hx HTN c/o 3 mos of CP, palpitations, abdominal pain. ESR-104, CRP 85 mg/L. CT showed thickening of the thoracic & abdominal aorta. After 6wks Rx w/ AZA, HCQ, Pred, ESR/CRP still high and pt stared on SC TCZ w/ improvement. https://t.co/IWm3ZQLBUN
Dr. John Cush RheumNow ( View Tweet)
Multinational retrospective review of CV risk in IIM (myositis) cohorts finds among 336 pts that > 1/3 are at moderate-high risk for CVD - but 34 % prescribed a statin. Moderate-high risk scores seen w/ necrotizing myopathy (OR 4.6), steroids (OR 1.8), dyslipidaemia (1.2) https://t.co/4IMiaHJvL3
Dr. John Cush RheumNow ( View Tweet)
Diffuse Alveolar Hemorrhage in Rheumatic Disease A retrospective, cross-sectional, single-center study of adult rheumatic disease patients with diffuse alveolar hemorrhage (DAH), demonstrates a high proportion have coexistent pulmonary infection and significant mortality risk. https://t.co/K1fLo5iHpd
Dr. John Cush RheumNow ( View Tweet)
Diffuse Alveolar Hemorrhage in Rheumatic Disease A retrospective, cross-sectional, single-center study of adult rheumatic disease patients with diffuse alveolar hemorrhage (DAH), demonstrates a high proportion have coexistent pulmonary infection and significant mortality risk. https://t.co/vpzF8Dnspr
Dr. John Cush RheumNow ( View Tweet)
Systematic review of cardiovascular death in systemic immune-mediated Dz (SIDs): 39 studies, 171,748 pts - SIDs assoc w/ signif. higher CV mortality (HR 1.26; 1.09-1.47; p = 0.002), especially for RA, SLE, GPA & females. 92% of CV deaths from acute coronary syndrome (ACS) https://t.co/ogLhqKMwON
Dr. John Cush RheumNow ( View Tweet)
Retrospective single center --103 EGPA pts finds 36 (35%) w/ cardiac involvement, having cardiac Sxs & biomarkers. Most common: pericarditis (77%), cardiomyopathy w/ CHF (55%), myocarditis (36%), cardiogenic shock (14%), cardiac arrest (6%), coronary v.asospasm (8%) https://t.co/JNdVNlVWvA
Dr. John Cush RheumNow ( View Tweet)
DANFLU-2 RCT of 332 438 elderly (43 881 w/ diabetes) tested high (HD-IIV) vs standard dose SD-IIV) flu vaccine. HD-IIV signif. reduced cardioresp., CV, CHF, influenza, hospitalizations vs SD-IIV, irrespective of DM status. Similar results previously seen in a Canadian RA pop. https://t.co/GGZPThoHrs
Dr. John Cush RheumNow ( View Tweet)
Anti-mitochondrial M2 Ab (AMA-M2) in 987 IIM pts-- 55 (6%) were AMA-M2 positive. AMA-M2+ had signif. higher rates of polymyositis (56% vs 23.5%), GGT, alk phos levels, & 3 fold more cardiac involvement (60 vs 13%) (arrhythmias, CHF, pulm HTN (31-56%), but no effect on survival https://t.co/8fQzgRfHr4
Dr. John Cush RheumNow ( View Tweet)
Shortened Leukocyte telomere length (PBL-TL) is assoc w/ systemic sclerosis–ILD. Study of PBL-TL in 244 SSc vs 314 controls, found signif shorter PBL-TL in SSC. Short PBL-TL was assoc w/ ILD & Pulm HTN, more lung related hospitalizations, but not w/ Raynauds, skin or vascular dz

Dr. John Cush RheumNow ( View Tweet)

Anti-mitochondrial M2 Ab (AMA-M2) in 987 IIM pts-- 55 (6%) were AMA-M2 positive. AMA-M2+ had signif. higher rates of polymyositis (56% vs 23.5%), GGT, alk phos levels, & 3 fold more cardiac involvement (60 vs 13%) (arrhythmias, CHF, pulm HTN (31-56%), but no effect on survival https://t.co/WYWeDpiYOh
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×